[논문]Sulbactam in combination with mezlocillin, piperacillin or cefotaxime: clinical and bacteriological findings in the treatment of serious bacterial infections

Manncke, K.; Springsklee, M.; Heizmann, W.R.; Sonntag, H.G.

doi:10.1016/s0924-8579(96)80008-2

Sulbactam in combination with mezlocillin, piperacillin or cefotaxime: clinical and bacteriological findings in the treatment of serious bacterial infections

International journal of antimicrobial agents, v.6 suppl., 1996년, pp.S47 - S54

Manncke, K. (Corresponding author.) , Springsklee, M. (Abteilung Klinische Forschung der Pfizer GmbH, Karlsruhe, Germany) , Heizmann, W.R. (Gemeinschaftslabor Prof. Enders, Dr. Metke, PD Dr. Gä) , Sonntag, H.G. (rtner, PD Dr. Heizmann, Stuttgart, Germany)

Abstract ▼ AI-Helper

AbstractAn open, multicentre study was performed in hospital in-patients at a total of 12 German hospitals to investigate the efficacy and tolerability of sulbactam combined with mezlocillin, piperacillin or cefotaxime in severe bacterial infections. A total of 155 patients were recruited into the study, of whom 48 were suffering from respiratory tract infections, 66 from intra-abdominal infections, 34 from skin/soft tissue infections including postoperative wound infections, and five from complicated urinary tract infections. Fifty-five patients intravenously received 4 g mezlocillin and 1 g sulbactam three times daily, 52 received 4 g piperacillin and 1 g sulbactam three times daily, and 48 received 2 g cefotaxime and 1 g sulbactam three times daily. The antibiotic and sulbactam combination was administered in all cases by rapid intravenous infusion of both components together, over 20 min. The mean duration of treatment was 20 days. The criteria used to define the outcome of treatment as successful were clinical cure (complete disappearance of the signs and symptoms of infection seen before the start of treatment) or improvement (appreciable diminution or partial resolution of the initial signs and symptoms, no further antibiotic therapy required) and the elimination of the organisms isolated before the start of the study. Of the 153 clinically evaluable patient, 141 (92%) were classed as responders (a cure was obtained in 98 cases and improvement in 43 cases). No response to the study medication was seen in 12 patients (7.8%). The response rates of the combined antibiotic-sulbactam preparations were 91% for mezlocillin/sulbactam, 92% for piperacillin/sulbactam, and 93% for cefotaxime/sulbactam. These response rates are almost identical. A total of 106 patients (68.4%) were bacteriologically evaluable; a total of 192 bacterial organisms were identified in these patients before the start of treatment. Mixed infection was present in 55 patients. The causative organism initially isolated was eliminated in 96 patients (90%), accounting for 180 of 192 strains (94%). Persistence of the causative organism (12 strains) was seen in eight patients (7.6%). Superinfection (four strains) was seen in two patients (1.9%). The study medication was well tolerated; adverse drug effects were seen in only five patients (3.3%). Treatment was discontinued in one patient because of the adverse effect (exanthema). The combination of the β-lactamase inhibitor sulbactam and a ureidopenicillin or cefotaxime was highly effiacious in patients with severe bacterial infections investigated in this study. The availability of sulbactam as a single-agent preparation opens up new avenues for flexible and cost-effective antibiotic therapy and is a valuable contribution to the control of bacterial resistance.

주제어

참고문헌 (32)

Medeiros 49 1986 Beta-Lactam Antibiotics for Clinical Use Beta-lactamase-mediated resistance
Am J Med Neu 7 11 1984 10.1016/0002-9343(84)90240-7 Changing mechanisms of bacterial resistance

상세보기
Neu 5 1986 Proc. 14th Int Congr Chemotherapy Resistance of bacteria due to β-lactamases
N Engl J Med Jacoby 324 601 1991 10.1056/NEJM199102283240906 New mechanisms of bacterial resistance to antimicrobial agents

상세보기
Infection Philippon 17 437 1989 10.1007/BF01650727 Epidemiology of extended spectrum β-lactamases

상세보기
Antimicrob Agents Chemother Philippon 33 1131 1989 10.1128/AAC.33.8.1131 Extended spectrum β-lactamases

상세보기
Infection Bauernfeind 15 257 1987 10.1007/BF01644127 Factor borne β-lactamase of Escherichia coli conferring resistance to cephalosporins

상세보기
Infection Bush 17 429 1989 10.1007/BF01645566 Biochemical characteristics of extended broad spectrum β-lactamases

상세보기
Mol Microbiol Collatz 4 1615 1990 10.1111/j.1365-2958.1990.tb00537.x Molecular evolution of ubiquitous β-lactamases towards extended-spectrum enzymes active against newer β-lactam-antibiotics

상세보기
Rev Infect Dis Gutmann 10 860 1988 10.1093/clinids/10.4.860 Plasmid-mediated β-lactamase (TEM-7) involved in resistance to ceftazidine and aztreonam
Antimicrob Agents Chemother Kliebe 28 302 1985 10.1128/AAC.28.2.302 Evolution of plasmid-coded resistance to broad spectrum cephalosporins

상세보기
Antimicrob Agents Chemother Petit 32 626 1988 10.1128/AAC.32.5.626 Novel plasmid-mediated β-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporins

상세보기
J Antimicrob Chemother Sirot 20 323 1987 10.1093/jac/20.3.323 Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae identification of CTX-1 a novel β-lactamase
Eur J Clin Microbiol Infect Dis Arlet 9 797 1990 10.1007/BF01967377 Outbreak of nosocomial infections due to Klebsiella pneumoniae producing SHV-4 beta-lactamase

상세보기
Drugs Campoli-Richards 33 577 1987 10.2165/00003495-198733060-00003 Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use

상세보기
Rev Infect Dis Lees 8 suppl. 5 644 1986 10.1093/clinids/8.Supplement_5.S644 Sulbactam plus ampicillin interim review of efficacy and safety for therapeutic and prophylatic use
Med Klin Lode 84 236 1989

상세보기
Infection Bauernfeind 17 316 1989 10.1007/BF01650718 Extended broad spectrum β-lactams in Klebsiella pneumoniae including resistance to cephamycins

상세보기
Antimicrob Agents Chemother Fantin 34 581 1990 10.1128/AAC.34.4.581 Carbon activity of sulbactam in combination with cefinaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2 like β-lactamase

상세보기
Diagn Microbiol Infect Dis Klastersky 12 165 1989 10.1016/0732-8893(89)90130-2 In vitro activity of sulbactam in combination with various β-lactam antibiotics

상세보기
Drug Res Schmalreck 40 1145 1990 In vitro activity against clinically important Gram-positive and Gram-negative bacteria of sulbactam alone and in combination with ampicillin, cefotoxin, mezocillin and piperacillin
Infection Pechere 17 333 1989 10.1007/BF01650724 Resistance to third generation cephalosporins: the current situation

상세보기
Infection Heizmann 15 370 1987 10.1007/BF01647747 In vitro activity of ampicillin plus sulbactam against anaerobes compared to ampicillin and cefoxitin

상세보기
Drug Res Wildfeuer 39 94 1989 Studies on the synergism of sulbactam and β-lactam antibiotics under in vitro conditions and in healthy volunteers after i.v. administration
Antimicrob Agents Chemother Foulds 23 692 1983 10.1128/AAC.23.5.692 Pharmacokinetics of sulbactam in humans

상세보기
Am J Med Solomkin 78 suppl. 6A 85 1985 10.1016/0002-9343(85)90106-8 Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infections

상세보기
JAMA Karch 234 1238 1975 10.1001/jama.234.12.1236 Adverse drug reactions: a critical review
Krankenhausarzt Wittke 63 55 1990 Behandlung von Infektionen in der Chirurgie
Rev Infect Dis Chiodini 7 suppl. 3 490 1985 10.1093/clinids/7.Supplement_3.S490 Imipenem/cilastatin in the treatment of serious bacterial infections
J Antimicrob Chemother Graninger 26 suppl. D 123 1990 10.1093/jac/26.suppl_D.123 Intravenous ofloxacin in severe infections
Antimicrob Agents Chemother Lode 31 1491 1987 10.1128/AAC.31.10.1491 Prospective randomized controlled study of ciprofloxacin versus imipenemcilastatin in severe clinical infections

상세보기
Lode S519 1987 Paul-Ehrlich-Gesellschaft/D Adam (Hrsg) Ciprofloxacin FAC 6-3 Fortschr Antimikrob Antineoplast Die klinische Bedeutung von Ciprofloxacin parenteral bei schweren Infektionen

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Sulbactam in combination with mezlocillin, piperacillin or cefotaxime: clinical and bacteriological findings in the treatment of serious bacterial infections

Abstract ▼ AI-Helper

주제어

참고문헌 (32)

이 논문을 인용한 문헌

관련 콘텐츠

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트